Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Liver Neoplasms 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Glioma 1Glioblastoma 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Bronchiolitis Obliterans Syndrome 1Brain Neoplasms 1

Interventions

Temozolomide 73Bevacizumab 57Radiotherapy 40Radiosurgery 28Carboplatin 23Nivolumab 17Etoposide 17Cisplatin 17pembrolizumab 16Irinotecan 16Ipilimumab 15Magnetic Resonance Spectroscopy 14Erlotinib Hydrochloride 14Cyclophosphamide 14Carmustine 14Pemetrexed 13Topotecan 10Surgical Procedures, Operative 10Capecitabine 10Lapatinib 9Filgrastim 9Trastuzumab 8Thalidomide 8Sunitinib 8Paclitaxel 8Lomustine 8Aminolevulinic Acid 8encorafenib 7binimetinib 7Vincristine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Brain Neoplasms × lonafarnib × Clear all
NCT00038493 2018-10-29

Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme

M.D. Anderson Cancer Center

Phase 2 Completed
23 enrolled
CNS

Brain Neoplasms, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡